Xeris Biopharma Holdings, Inc. ($XERS)
Filing Information
| Accession Number | 0001652410-26-000004 |
|---|---|
| Form Type | 4 |
| Filing Date | Feb 2, 2026 |
| Document Date | Jan 30, 2026 |
| Document | View SEC Filing |
Transactions
6
Total Shares
469,677
Total Value
$1,372,072.28
P&L
+inf% (+$1,541,995.20)
Transactions
| Name | Title | Security | Derivative | Transaction Date | Type | Shares | Price | Total Cost | Shares After | Direct/Indirect | Nature of Ownership | Actions |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chief Legal Officer and Corporate Secretary | Common Stock | โ | Jan 30, 2026 | Grant/Award | 121,293 | $0.00 | $0.00 | 1,429,396 | Direct | โ | View Details | |
Chief Legal Officer and Corporate Secretary | Common Stock | โ | Jan 31, 2026 | Tax Withholding | 98,375 | $7.36 | $724,040.00 | 1,331,021 | Direct | โ | View Details | |
Chief Legal Officer and Corporate Secretary | Common Stock | โ | Jan 31, 2026 | Tax Withholding | 46,914 | $7.36 | $345,287.04 | 1,284,107 | Direct | โ | View Details | |
Chief Legal Officer and Corporate Secretary | Common Stock | โ | Jan 31, 2026 | Tax Withholding | 24,266 | $7.36 | $178,597.76 | 1,259,841 | Direct | โ | View Details | |
Chief Legal Officer and Corporate Secretary | Common Stock | โ | Feb 2, 2026 | Sale | 16,667 | $7.45 | $124,147.48 | 1,243,174 | Direct | โ | View Details | |
Chief Legal Officer and Corporate Secretary | Stock Option (Right to Buy) | Derivative | Jan 30, 2026 | Grant/Award | 162,162 | $0.00 | $0.00 | 162,162 | Direct | โ | View Details |